Bloodborne viral hepatitis infections among drug users: The role of vaccination

International Journal of Environmental Research and Public Health

Volumn 6, Issue 1, 2009, Pages 400-413

  Lugoboni, Fabio ^a   Quaglio, Gianluca ^a   Civitelli, Paolo ^b   Mezzelani, Paolo ^a  

^a Department of Internal Medicine   (Italy)

^b Addiction Treatment Clinic (SerT Asl4)   (Italy)

Author keywords

Drug users; HAV; HBV; Hepatitis vaccination; Immunization

Indexed keywords

HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 61449143671     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph6010400     Document Type: Review

References (92)

1. Aceijas, C.; Stimson, G.V.; Hickman, M.; Rhodes, T. Global overview of injecting drug use and HIV infection among drug users. AIDS 2004, 18, 2295-2303.
2. United Nations Office on Drug and Crime. World drug report. United Nations Publication: Vienna, Austria, 2006.
3. Centers for Diseases Control and Prevention. Viral hepatitis and injecting drug users. MMWR Morb. Mortal. Wkly. Rep. 2002.
4. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report 2003: the state of the drugs problem in the European Union and Norway. EMCDDA: Lisbon, Portugal, 2003; pp. 24-28.
5. Quaglio, G.L.; Lugoboni, F.; Pattaro C.; Montanari L.; Lechi, A.; Mezzelani, P.; Des Jarlais, D.C. Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients. BMC Public Health 2006, 23, 206-216.
6. Diaz, T.; Des Jarlais, D.C.; Vlahov, D. Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am. J. Public Health 2001, 91, 23-30.
7. Quaglio, G.L.; Lugoboni, F.; Pajusco, B.; Sarti, M.; Talamini, G.; Lechi, A.; Mezzelani, P.; Des Jarlais, D.C. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin. Infect. Dis. 2003, 37, 33-40.
8. Edlin, B.R.; Kresina, T.F.; Raymond, D.B. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin. Infect. Dis. 2005, 40, S276-285.
9. Devi, K.S.; Brajachand, N.; Singh, H.L.; Singh, Y.M. Co-infection by human immunodeficiency virus, hepatitis B and hepatitis C virus in injecting drug users. J. Commun. Dis. 2005, 37, 73-77.
10. Quaglio, G.L.; Talamini, G.; Lechi, A.; Venturini, L. ; Lugoboni, F.; Mezzelani, P. ; GICS. Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death. Addiction 2001, 96, 1127-1137.
11. Quaglio, G.L.; Lugoboni, F.; Pajusco, B.; Sarti, M.; Talamini, G.; Mezzelani, P.; Des Jarlais, D.C.; GICS. Hepatitis C virus infection: prevalence, predictor variables and preventive opportunities among drug users in Italy. J. Viral. Hepat. 2003, 10, 394-400.
12. Gyarmathy, V.A.; Neaigus, A.; Miller, M.; Friedman, S.R.; Des Jarlais, D.C. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J. Acquir. Immune Defic. Syndr. 2002, 30, 448-456.
13. Winstock, A.R.; Anderson, C.M.; Sheridan, J. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia. Med. J. Aust. 2006,184, 560-562.
14. Cuthbert, J.A. Hepatitis A: old and new. Clin. Microb. Rev. 2001, 14, 38-58.
15. Granerød, J.; Crowcroft, N. Hepatitis A epidemiology in England and Wales. Eurosurveillance Weekly 2002, 6, 50.
16. Crowcroft N.S. Hepatitis A virus infections in injecting drug users. Commun. Dis. Public Health 2003, 6, 82-84.
17. Hutin, Y.J.; Sabin, K.M.; Hutwagner, L.C. Multiple modes of hepatitis A virus transmission among methamphetamine users. Am. J. Epidemiol. 2000, 152, 186-192.
18. Perrett, K.; Graner0d, J.; Crowcroft, N.; Carlisle, R. Changing epidemiology of hepatitis A: should we be doing more to vaccinate injecting drug users? Commun. Dis. Public Health 2003, 6, 97-100.
19. van Steenbergen, J.E.; Tjon, G.; van Den Hoek, A.; Koek, A.; Coutinho, R.A.; Bruisten, S.M. Two years' prospective collection of molecular and epidemiological data shows limited spread of hepatitis A virus outside risk groups in Amsterdam, 2000-2002. J. Infect. Dis. 2004, 189, 471-482.
20. WHO. Hepatitis A vaccines WHO. position paper. Weekly Epidemiol. Rec. 2000, 5, 38-44.
21. Vento, S; Garofano, T; Renzini, C. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N. Engl. J. Med. 1998, 338, 286-290.
22. Quaglio, G.L.; Pajusco, B.; Civitelli, P.; Migliozzi, S.; Des Jarlais, D.C.; Romano, L.; Lechi, A.; Mezzelani, P.; Lugoboni F. Immunogenicity, reactogenicity and adherence with hepatitis A vaccination among drug users. Drug Alcohol Depend 2004, 74, 85-88.
23. Lugoboni, F.; Quaglio, G.L.; Pajusco, B.; Foroni, M.; Blengio, G.; Talamini, G.; Mezzelani, P.; Des Jarlais, D.C. Prevalence of hepatitis A among drug users in north-eastern Italy. Eur. J. Public Health 2005, 15, 464-466.
24. Gaeta, G.B; Stroffolini, T.; Chiaramonte, M. Chronic hepatitis D: a vanishing disease? An italian multicenter study. Hepatology 2000, 32, 824-827.
25. Poovorawan, Y.; Chatchatee, P.; Chongsrisawat, V. Epidemiology and prophylaxis of viral hepatitis: a global prospective. J. Gastroenterol. Hepatol. 2002, 17, 155-166.
26. Farci, P. Delta hepatitis: an update. J. Hepatol. 2003, 39, S212-219.
27. Garfein, R.S.; Bower, W.A.; Loney, C.M.; Hutin, Y.J.; Xia, G.L.; Jawanda, J.; Groom, A.V.; Nainan, O.V.; Murphy, J.S.; Bell, B.P. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatol. 2004, 40, 790-792.
28. Broers, B.; Junet, C.; Bourquin, M.; Deglon, J.J.; Perrin, L.; Hischel B. Prevalence and incidence rate of HIV, HBV and HCV among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 1998, 12, 2059-2066.
29. Quaglio, G.L.; Lugoboni, F.; Mezzelani, P.; Des Jarlais, D.C.; Lechi, A. Hepatitis vaccination among drug users. Vaccine 2006, 24, 2702-2709.
30. Mansson, A.S.; Moestrup, T.; Nordenfelt, E.; Widell, A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users partecipating in a syringe/needle exchange program. Scand. J. Infect. Dis. 2000, 32, 253-258.
31. Centers for Disease Control and Prevention. Achievements in public health: hepatitis B vaccination-United States, 1982-2002. MMWR Morb. Mortal. Wkly. Rep. 2002, 51, 549-563.
32. Centers for Disease Control and Prevention. Incidence of acute hepatitis B-United States, 1990-2002. MMWR Morb. Mortal. Wkly Rep. 2004, 52, 1252-1254.
33. Rich, J.D.; Anderson, B.J.; Schwartzapfel, B.; Stein, M.D. Sexual risk for hepatitis B virus among hepatitis C virus-negative heroin and cocaine users. Epidemiol. Infect 2006, 143, 478-484.
34. Gyarmathy, V.A.; Neaigus, A.; Miller, M.; Friedman, S.R.; Des Jarlais, D.C. Risk correlates of prevalent HIV, hepatitis B virus and hepatitis C virus infections among noninjecting heroin users. J. Acquir. Immune Defic. Syndr. 2002, 30, 448-456.
35. Oliveira, M.L.; Bastos, F.I.; Telles, P.R.; Yoshida, C.F.; Schwartzmayer, H.G.; Paetzold, U.; Pauli, G.; Schreier, E. Prevalence and risk factors for HBV, HCV and HDV infections among injecting drug users from Rio de Janeiro, Brazil. Braz. J. Med. Biol. Res. 1999, 32, 1107-1114.
36. Lugoboni, F.; Quaglio, G.L.; Mezzelani, P.; Lechi, A. No positive tests for syphilis in 6 years of observation among heroin users in north-eastern Italy. Addiction 2002, 97, 104-105.
37. Maher, L.; Chant, K.; Jalaludin, B.; Sargent, P. Risk behaviours and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J. Gastroenterol. Hepatol. 2004, 19, 1114-1120.
38. Carter, H.; Robinson, G.; Hanlon, C.; Hailwood, C.; Massarotto, A. Prevalence of hepatitis B and hepatitis C in a methadone clinic population : implication for hepatitis B vaccination. N. Z. Med. J. 2001, 114, 324-326.
39. Gerlich, M.; Gschwend, P.; Uchtenhagen, A.; Kramer, A.; Rehm, J. Prevalence of hepatitis B and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994-2002. Eur. J. Epidemiol. 2006, 21, 545-549.
40. Weissenbacher, M.; Rossi, D.; Radulich, G.; Sosa-Estefani, S.; Vila, M.; Vivas, E.; Avila, M.M.; Cuchi, P.; Rey, J.; Peralta, L.M. High seroprevalence of bloodborne viruses among street- recruited injection drug users from Buenos Aires, Argentina. Clin. Infect. Dis. 2003, 37, 348-352.
41. Shapatava, E.; Nelson, K.E.; Tsertsvadze, T.; del Rio C. Risk behaviour and HIV, hepatitis B and hepatitis C seroprevalence among injection drug users in Georgia. Drug Alcohol Depend 2006, 82, 35-38.
42. Baral, S.; Sherman, S.G.; Millson, P.; Beyer, C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect. Dis. 2007, 7, 667-674.
43. Grogan, L.; Tiernan, M.; Geogeghan, N.; Smyth, B.; Keenan, E. Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunization uptake. Ir. J. Med. Sci. 2005, 174, 14-20.
44. Backmund, M.; Meyer, K.; Schuetz, C.; Reimer, J. Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend 2006, 84, 154-159.
45. Lum, P.J.; Ochoa, K.O.; Hahn, J.A.; Shafer, K.P.; Evans, J.L.; Moss, A.R. Hepatitis B virus. Immunization among young injection drug users in San Francisco, Calif: The UFO Study. Am. J. Public Health 2003, 93, 919-923.
46. Lum, P.J; Hahn, J.A.; Shafer, K.P.; Evans, J.L.; Davidson, P.J.; Stein, E.; Moss, A.R. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J. Viral Hepat. 2008, 15, 229-236.
47. Roy, K.M.; Goldberg, D.J.; Wilson, K.; Cameron, S.O. Vaccination induced immunity to the hepatitis B virus among high-risk groups in Glasgow 1993-2001: evaluating the effectiveness of the UK's selective immunization policy. Scott. Med. J. 2008, 53, 13-17.
48. Vallejo, F.; Toro, C.; de la Fuente, L.; Brugal, M.T.; Bravo, M.J. Hepatitis B vaccination: an unmet challenge in the era of harm reduction programs. J. Subst. Abuse Treat 2008, 34, 398-406.
49. Mezzelani, P.; Venturini, L.; Turrina, G.; Lugoboni, F.; Des Jarlais, D.C. High compliance with a hepatitis B virus vaccination program among intravenous drug users. J. Infect. Dis. 1991, 163, 993.
50. Lugoboni, F.; Migliozzi, S.; Schiesari, F.; Pauletto, N.; Bovo, G.L.; Mezzelani, P. Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users. Vaccine 1997, 15, 1014-1016.
51. Quaglio, G.L.; Talamini, G.; Lugoboni, F.; Lechi, A.; Venturini, L.; GICS, Des Jarlais, D.C.; Mezzelani, P. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction 2002, 97, 985-992.
52. Quaglio, G.L.; Lugoboni, F.; Pajusco, B.; Sarti, M.; Mezzelani, P. Managerial considerations in implementing hepatitis B vaccination programs among drug-using cohorts. Addiction 2002, 97, 1613-1614.
53. Lugoboni, F.; Quaglio, G.L.; Pajusco, B.; Civitelli, P.; Romano, L.; Bossi, C.; Spilimbergo, I.; Mezzelani, P. Immunogenicity, reactogenicity and adherence of a combined hepatitis A and B vaccine in illicit drug users. Addiction 2004, 99, 1560-1564.
54. Quaglio, G.L.; Lugoboni, F.; Mezzelani, P. HBV vaccination should be performed in service centres for drug users: an Italian experience. J. Public Health 2004, 26, 320.
55. Hu, Y.; Grau, L.E.; Scott, G.; Seal, K.H.; Marshall, P.A.; Singer, M.; Heimer, R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am. J. Prev. Med. 2008, 35, 25-32.
56. Gabbuti, A.; Romano, L.; Blanc, P.; Meacci, F.; Amendola, A.; Mele, A.; Mazzotta, F.; Zanetti, A.R. Long-term immunogenicity of hepatitis B vaccination in a cohort of italian healty adolescents. Vaccine 2007, 25, 3129-3132.
57. Da Villa, G.; Romano, L.; Sepe, A.; Iorio, R.; Paribello, N.; Zappa, A.; Zanetti, A.R. Impact of hepatitis B vaccination in highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007, 25, 3133-3136.
58. Zanetti, A.R.; van Damme, P.; Shouval, D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26, 6266-6267.
59. Lemon, S.M.; Thomas, D.L. Vaccines to prevent viral hepatitis. N. Engl. J. Med. 1997, 33, 196-204.
60. Daryani, N.E.; Nassiri-Toosi, M.; Rashidi, A.; Khodarahmi, I. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case control study. World J. Gastroenterol 2007, 13, 294-298.
61. Baca, C.T.; Yahne, C.E. Smoking cassation during substance abuse treatment: what you need to know. J. Subst. Abuse Treat 2008 Epub ahead of print.
62. Kuo, I.; Mudrick, D.W.; Strathdee, S.A.; Thomas, D.L.; Sherman, S.G. Poor validity of self- reported hepatitis B virus infection and vaccination status among young drug users. Clin. Infect. Dis. 2004, 38, 587-590.
63. Minniti, F.; Baldo, V.; Trivello, R. Response to HBV vaccine in relation to anti-HCV and anti- HBc positivity: a study in intravenous drug addicts. Vaccine 1999, 17, 3083-3085.
64. Leroy, V.; Bourlier, M.; Durand, M.; Abergel, A.; Tran, A.; Baud, M.; Botta-Fridlund, D.; Gerolami, A.; Ouzan, D.; Halfon, P.; Zarski, J.P. The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study. Eur. J. Gastoenterol. Hepatol. 2002, 14, 485-489.
65. Idilman, R.; De Maria, N.; Colantoni, A.; Nadir, A.; Van Thiel, D.H. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am. J. Gastroenterol 2002, 97, 435-439.
66. Elefsiniotis, I.S.; Vezali, E.; Kamposioras, K.; Pantazis, K.D.; Tontorova, R.; Keticoglu, I.; Moulakakis, A.; Saroglou, G. Immunogenicity of recombinant hepatitis B vaccine in treatment- naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J. Gastroenterol 2006, 12, 4420-4424.
67. van Houdt, R.; Sonder, G.J.; Dukers, N.H.; Bovee, L.P.; van den Hoek, A.; Coutinho, R.A.; Briusten, S.M. Impact of a targeted hepatitis B vaccination program in Amsterdam, The Netherlandas. Vaccine 2007, 25, 2698-2705.
68. Paitoongpong, L.; Suankratay, C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand. J. Infect. Dis. 2008, 40, 54-58.
69. Lugoboni, F.; Migliozzi, S.; Mezzelani, P.; Pajusco, B.; Ceravolo, R.; Quaglio, G.L. Progressive decrease of Hepatitis B in a cohort of drug users followed over a period of 15 years: the impact of anti-HBV vaccination. Scand. J. Infect. Dis. 2004, 36, 131-133.
70. Quaglio, G.L; Lugoboni, F.; Vento, S.; Lechi, A.; Accordini, A.; Bossi, C.; Faccini, M.; Mezzelani, P. Isolated presence of antibody to hepatitis b core antigen in injection drug users: do they need to be vaccinated? Clin. Infect. Dis. 2001, 32, 143-144.
71. Gandhi, R.T.; Wurcel, A.; Lee, H. Isolated Antibody to Hepatitis B Core Antigen in Human Immunodeficiency Virus Type-1-Infected Individuals. Clin. Infect. Dis. 2003, 36, 1602-1605.
72. Silva, A.E.; McMahon, B.J.; Parkinson, A.J.; Sjogren, M.H.; Hoofnagle, J.H.; Di Bisceglie, A.M. Hepatitis B virus DNA in persons with isolated antibody to hepatitis B core antigen who subsequently received hepatitis B vaccine. Clin. Infect. Dis. 1998, 26, 895-897.
73. Torbenson, M.; Kannangai, R.; Astemborski, J.; Strathdee, S.A.; Vlahov, D.; Thomas, D.L. High Prevalence of Occult Hepatitis B in Baltimore injection drug users. Hepathol 2004, 39, 51-57.
74. Pereira, J.S.; Goncales, N.S.; Silva, C.; Lazarini, M.S.; Pavan, M.H.; Fais, V.C.; Goncales Junior, F.L. HBV vaccination of HCV-infected patients with occult HBV infection and anti-HBc-positive blood donors. Braz. J. Med. Biol. Res. 2006, 39, 525-531.
75. van Steenbergen, J.E. Working group vaccination high-risk groups hepatitis B for the Netherlands. Results of an enhanced-outreach programme of hepatitis B vaccination in the Netherlands (1998-2000) among men who have sex with men, hard drug users, sex workers and heterosexual persons with multiple partners. J. Hepatol. 2002, 37, 507-513.
76. Rich, J.D.; McKenzie, M.; Macalino, G.E. A syringe prescription program to prevent infectious disease and improve health of injection drug users. J. Urban Health 2004, 81, 112-134.
77. François, G.; Hallauer, J.; Van Damme, P. Hepatitis B vaccination: how to reach risk groups. Vaccine 2002, 21, 1-4.
78. Des Jarlais, D.C.; Fisher, D.G.; Newman, J.C. Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program. Am. J. Public Health 2001, 91, 1791-1792.
79. Kuo, I.; Sherman, S.G.; Thomas, D.L.; Strathdee, S.A. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend 2004, 73, 69-78.
80. Altice, F.L.; Bruce, R.D.; Walton, M.R.; Buitrago, M.I. Adherence to hepatitis B virus vaccination at syringe exchange sites. J. Urban Health 2005, 82, 151-161.
81. Weinbaum, C.; Lyerla, R.; Margolis, H.S. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Mortal. Wkly. Rep. 2003, 52, 1-36.
82. Rothman, R.E.; Ketlogetswe, K.S.; Dolan, T.; Wyer, P.C.; Kelen, G.D. Preventive care in the emergency department: should emergency departments conduct routine HIV screening? A systematic review. Acad. Emerg. Med. 2003, 10, 278-285.
83. Centers for Disease Control. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb.Mortal. Wkly Rep. 1999, 48, 1-37.
84. Craig, A.S.; Schaffner, W. Prevention of hepatitis A with the hepatitis A vaccine. N. Engl. J. Med. 2004, 350, 476-481.
85. Crowcroft, N.S. Hepatitis A virus infections in injecting drug users. Commun. Dis. Public Health 2003, 6, 82-84.
86. Bower, W.A.; Nainan, O.V.; Han, X; Margolis, H. Duration of viremia in hepatitis A virus infection. J. Infect. Dis. 2000, 182, 12-17.
87. Andre, F.; van Damme, P.; Safary, A.; Banatvala, J. Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use. Expert Rev. Vaccines 2002, 1, 9-23.
88. Lugoboni, F.; Quaglio, G.L.; Residori, M.; Mecenero, V.; Mezzelani, P. Hepatitis A virus vaccination among injecting drug users: do we have to change the vaccination schedule? Clin. Infect. Dis. 2000, 31, 847-848.
89. Keeffe, E.B.; Iwarson, S.; McMahon, B.J. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatol. 1998, 27, 881-886.
90. Berzofsky, J.A.; Ahlers, J.D.; Janik, J. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 2004; 114, 450-462.
91. Joines, R.W.; Blatter, M.; Abraham, B. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine 2001, 19, 4710-4719.
92. Guadagino, V.; Trotta, M.P.; Montesano, F.; Babudieri, S.; Caroleo, B.; Armignacco, O.; Carioti, J.; Maio, G.; Monarca, R.; Antinori, A.; Nocchiero Study Group. Effectivenes of a multi-disciplinary standarized management model in the treatment of chronic epatiti C in drug addicts engaged in detoxification programmes. Addiction 2007, 102, 423-431.